Arrowhead Pharmaceuticals Q1 2022 Earnings Report
Key Takeaways
Arrowhead Pharmaceuticals reported its fiscal year 2022 first quarter results with a revenue of $27.439 million and a net loss of $62.872 million, resulting in a net loss per share of $0.60.
Initiated the PALISADE Phase 3 clinical study to evaluate the efficacy and safety of ARO-APOC3 in adults with familial chylomicronemia syndrome.
Advanced two new investigational candidates that utilize Arrowhead’s pulmonary targeted TRiMTM platform into CTA enabling studies.
Completed a transaction to purchase 13 acres of land in the Verona Technology Park in Verona, WI, planned to be the site of a drug manufacturing facility and a laboratory and office facility.
Entered into an exclusive license agreement with GlaxoSmithKline (GSK) under which GSK will develop and commercialize ARO-HSD.
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals
Forward Guidance
Arrowhead Pharmaceuticals did not provide specific financial forward guidance in the press release.